Number of responders · IBD patients
1 finding from 1 review
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with anaemia
It is very uncertain whether oral iron changes mortality compared with inactive control (very low certainty).
1 finding from 1 review
Blood transfusion · patients with anaemia
It is very uncertain whether oral iron changes proportion requiring blood transfusion compared with inactive control (very low certainty).
1 finding from 1 review
Length of hospital stay · patients with anaemia
1 finding from 1 review
Haemoglobin (g/dL) · patients with anaemia
1 finding from 1 review
Quality of life · patients with anaemia
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether oral iron changes serious adverse events compared with inactive control (very low certainty).
1 finding from 1 review
Maternal mortality ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistent anaemia symptoms ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thromboembolic events ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Red blood cell transfusions (Subnet based on 69 studies including 18,684 participants) · patients at any age with solid cancer or haematological malignancy
IV or oral iron alone showed no clear difference in red blood cell transfusions (Subnet based on 69 studies including… compared with no treatment (low certainty).
1 finding from 1 review
RR 0.74 [0.43, 1.28]
Studies not reported
Low
Overall mortality4 (Subnet based on 71 studies including 21,576 participants) · patients at any age with solid cancer or haematological malignancy
IV or oral iron alone showed no clear difference in overall mortality4 (Subnet based on 71 studies including 21,576… compared with no treatment (low certainty).
1 finding from 1 review
RR 1.5 [0.63, 3.56]
Studies not reported
Low
Thromboembolic events · patients at any age with solid cancer or haematological malignancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension5 (Subnet based on 24 studies including 8383 participants) · patients at any age with solid cancer or haematological malignancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
On‐study mortality3 (Subnet based on 55 studies including 15,074 participants) · patients at any age with solid cancer or haematological malignancy
IV or oral iron alone showed no clear difference in on‐study mortality3 (Subnet based on 55 studies including 15,074… compared with no treatment (low certainty).
1 finding from 1 review
RR 2.95 [0.71, 12.34]
Studies not reported
Low
Haemoglobin response (Subnet based on 31 studies including 6985 participants) · patients at any age with solid cancer or haematological malignancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
RR 1.05 [0.52, 2.11]
728 participants
Low